HomeNewsIndiaNational Institute of Virology develops 1st indigenous antibody detection kit for COVID-19: Harsh Vardhan

National Institute of Virology develops 1st indigenous antibody detection kit for COVID-19: Harsh Vardhan

The test kit has the advantage of testing 90 samples together in a single run of 2.5 hours so that healthcare professionals can proceed quickly with necessary next steps, Vardhan said.

May 10, 2020 / 20:48 IST

The National Institute of Virology in Pune has successfully developed the first indigenous antibody detection kit for COVID-19 that will play a critical role in surveillance for coronavirus infection, Union Health Minister Harsh Vardhan said on Sunday.

The test kit has the advantage of testing 90 samples together in a single run of 2.5 hours so that healthcare professionals can proceed quickly with necessary next steps, Vardhan said.

"National Institute of Virology, Pune, has successfully developed the 1st indigenous anti-SARS-CoV-2 human IgG ELISA test kit for antibody detection of COVID-19," the minister said in one of a series of tweets.

"This robust test will play a critical role in surveillance of proportion of the population exposed to SARSCoV2 infection," he said.

This kit was validated at two sites in Mumbai and has high sensitivity and accuracy, Vardhan said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The ELISA-based testing is easily possible even at district level, he said.

Developed in a month's time, the testing kit would help to study the presence of anti-SARS-CoV-2 IgG antibodies in the Indian population.

It is cost-effective, sensitive, rapid, and a large number of samples can be tested at any level of clinical setting, public health centers and hospitals.

The Indian Council of Medical Research-National Institute of Virology, Pune, technology has been transferred to Zydus Cadila for mass-scale production.

The Drug Controller General has granted commercial production and marketing permission to Zydus, Vardhan said.

The ICMR recently has cancelled orders for about half a million COVID-19 rapid antibody test kits from China after they were found to be giving out inaccurate results.

The testing technique is used to detect antibodies in the blood of people who may have had coronavirus infection.

PTI
first published: May 10, 2020 08:42 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347